Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: deciphera.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | $14.00 | Neutral | JP Morgan |
| 10/30/2023 | $23.00 | Neutral → Overweight | Piper Sandler |
| 8/10/2023 | $14.00 → $20.00 | Hold → Buy | Stifel |
| 1/4/2023 | $22.00 | Neutral → Buy | Guggenheim |
| 8/29/2022 | $25.00 | Outperform | Cowen |
| 8/5/2022 | $23.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 2/28/2022 | $11.00 → $6.00 | Equal-Weight → Underweight | Barclays |
| 12/1/2021 | $25.00 → $15.00 | Buy | HC Wainwright & Co. |
| 11/8/2021 | $65.00 → $10.00 | Buy → Hold | Truist Securities |
| 11/8/2021 | $60.00 → $10.00 | Buy → Hold | Stifel |
15-12G - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
EFFECT - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Application (MAA) in the Third Quarter of 2024 – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being
OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit
Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera's Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical's Pipeline and Accelerate Global Reach Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of D
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET. A live webcast of the fireside chat will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 1:30 PM ET in Boston, MA Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 2:40 PM ET in Miami Beach, FL Barclays Global Healthcare Conference on Wednesday, March 13, 2024 at 8:00 AM ET in Miami Beach, FL Live webcasts will be available on the "Events and Presentat
– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 2024 and MAA in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT) – – Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study in 2L GIST Patients with Mutations in KIT Exon 11+17/18 Published in Nature Medicine; Final Overall Survival (OS) Results from INTRIGUE Study in 2L GIST Patients Presented at ASCO GI – – Cash Expected to Fund Operating and Capital Expenditures into the Second Half of 2026 – Deciphera
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, February 6, 2024, to discuss the Company's financial results and provide a corporate update. The conference call may be accessed via this link: https://register.vevent.com/register/BI7a0bbbeb53864df9a854d959bbbae709 A live webcast o
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 9:00 AM ET in New York, NY. A live webcast of the fireside chat will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company's website for 90 day
– Median Overall Survival for QINLOCK® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Population – – Long-Term Safety Profile Consistent with Primary Analysis Showing Fewer Patients with Grade 3/4 Treatment-Emergent Adverse Events (TEAEs) and Lower Rate of Treatment Discontinuations Due to TEAEs with QINLOCK Versus Sunitinib – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of new long-term results from the INTRIGUE Phase 3 clinical study comparing QINLOCK® (ripretinib)
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S
OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit
– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 2024 and MAA in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT) – – Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study in 2L GIST Patients with Mutations in KIT Exon 11+17/18 Published in Nature Medicine; Final Overall Survival (OS) Results from INTRIGUE Study in 2L GIST Patients Presented at ASCO GI – – Cash Expected to Fund Operating and Capital Expenditures into the Second Half of 2026 – Deciphera
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, February 6, 2024, to discuss the Company's financial results and provide a corporate update. The conference call may be accessed via this link: https://register.vevent.com/register/BI7a0bbbeb53864df9a854d959bbbae709 A live webcast o
– Third Quarter 2023 Total Revenue of $43.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 29% to $41.8 Million Compared to Third Quarter 2022 – – Announced Positive Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib for TGCT and Updated Results from Phase 1/2 Study; NDA Submission Expected in Second Quarter of 2024 – – QINLOCK Successfully Launched in Italy – – Conference Call to be Held Today at 8:00 AM ET – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the thir
– MOTION Study Met Primary Endpoint with Objective Response Rate (ORR) at Week 25 of 40% Compared to 0% for Placebo (p<0.0001) – – MOTION Study Met All Key Secondary Endpoints with Statistically Significant and Clinically Meaningful Improvements at Week 25 Compared to Placebo, including ORR by Tumor Volume Score (TVS) of 67% vs. 0% (p< 0.0001) – – Updated Results from Phase 1/2 Study of Vimseltinib Demonstrated Best ORR of 72% (Phase 1) and 64% (Phase 2 Cohort A) with Median Treatment Duration of 25.1 Months (Phase 1) and 21.0 Months (Phase 2 Cohort A) – – Treatment with Vimseltinib was Well-tolerated with No Evidence of Cholestatic Hepatotoxicity in MOTION and Phase 1/2 Studies – –
– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 – – Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 – – INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-line GIST Patients with Mutations in KIT Exon 11 and 17/18 Initiated with First Sites Open for Enrollment – – DCC-3116 Combination Escalation Cohorts with QINLOCK and with Encorafenib and Cetuximab Initiated with First Site Open for Enrollment; Combination Dose Escalation Cohorts with MEK and KRAS G12C Inhibitors Ongoing – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH),
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2023 financial results on Wednesday, August 9, 2023. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, August 9, 2023, to discuss the Company's financial results and provide a corporate update. The conference call may be accessed via this link: https://register.vevent.com/register/BI74ff2d04fe8541f48da1cf0ad35339ae A live webcast of the conferen
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 3, 2023, to discuss the Company's financial results and provide a corporate update. The conference call may be accessed via this link: https://register.vevent.com/register/BI75fb53c225a648b486e50d922b166468 A live webcast of the conference call
– First Preclinical Data for Pan-RAF Inhibitor DCC-3084 to be Presented; IND Filing Expected in Second Half of 2023 – – New Preclinical Data Supports ULK inhibitor DCC-3116 in Combination with QINLOCK® in GIST and in Combination with Encorafenib and Cetuximab in Colorectal Cancer; Expects to Initiate Two New Combination Escalation Studies in Second Half of 2023 – – New Pan-KIT Development Candidate DCC-3009 for GIST Demonstrates Potential Best-in-Class Profile with Broad Coverage of KIT Mutations with High Selectivity – – Company Discloses New Research Programs Focused on Novel Integrated Stress Response Targets GCN2 and PERK – – Company to Host Virtual Investor Event on Tuesday, April
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
SC 13G - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)
A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Oct. 6, 2023 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that
— Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company's Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company. Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023. Dr. Dhanak brings over 30 year
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company's business development efforts as well as supporting corporate strategy initiatives. "We are thrilled to welcome Kelley to our executive team as Chief Business Officer. Kelley has extensive leadership experience in pharmaceutical and biotechnology companies with a proven track record of building value through business development and strategic partnerships," said Steve Hoerter, President and Ch
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a business update. “We made significant progress in 2020 with the successful launch of QINLOCK, completing enrollment in the Phase 3 INTRIGUE study in second-line GIST patients, and generating promising new data for both vimseltinib and rebastinib,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “We’re incredibly excited by the opportunities ahead for the Company in 2021. Specifically, we look forward to top-line results from the INTRIGUE study and are activel
JP Morgan resumed coverage of Deciphera Pharmaceuticals with a rating of Neutral and set a new price target of $14.00
Piper Sandler upgraded Deciphera Pharmaceuticals from Neutral to Overweight and set a new price target of $23.00
Stifel upgraded Deciphera Pharmaceuticals from Hold to Buy and set a new price target of $20.00 from $14.00 previously
Guggenheim upgraded Deciphera Pharmaceuticals from Neutral to Buy and set a new price target of $22.00
Cowen initiated coverage of Deciphera Pharmaceuticals with a rating of Outperform and set a new price target of $25.00
JMP Securities upgraded Deciphera Pharmaceuticals from Mkt Perform to Mkt Outperform and set a new price target of $23.00
Barclays downgraded Deciphera Pharmaceuticals from Equal-Weight to Underweight and set a new price target of $6.00 from $11.00 previously
HC Wainwright & Co. reiterated coverage of Deciphera Pharmaceuticals with a rating of Buy and set a new price target of $15.00 from $25.00 previously
Truist Securities downgraded Deciphera Pharmaceuticals from Buy to Hold and set a new price target of $10.00 from $65.00 previously
Stifel downgraded Deciphera Pharmaceuticals from Buy to Hold and set a new price target of $10.00 from $60.00 previously
Guggenheim analyst Michael Schmidt downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Neutral.
JMP Securities analyst Reni Benjamin downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Market Outperform to Market Perform.
In the last three months, 5 analysts have published ratings on Deciphera Pharmaceuticals (NASDAQ:DCPH), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 2 0 0 2M Ago 0 0 1 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Deciphera Pharmaceuticals, presenting an average target of $23.24, a high estimate of $26.00, and a low estimate of $16.00. Obse
Barclays analyst Peter Lawson upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Underweight to Equal-Weight and raises the price target from $9 to $26.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday. The Dow traded up 0.19% to 38,313.56 while the NASDAQ rose 0.13% to 15,948.81. The S&P 500 also rose, gaining, 0.10% to 5,105.25. Check This Out: Jim Cramer Likes Palantir, Recommends Pioneer Natural Resources: ‘I Want You To Ka-Ching, Ka-Ching’ Leading and Lagging SectorsConsumer discretionary shares rose by 1.9% on Monday. In trading on Monday, communication services shares fell by 1.7%. Top Headline ON Semiconductor Corp (NASDAQ:ON) reported better-than-expected first-quarter results. ON Semiconductor reported a fiscal first-quarter 2024 revenue decline of 5%
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc. (NASDAQ:AAPL) on Thursday, a pivotal Federal Reserve Open Market Committee meeting on Wednesday, and the April’s jobs report on Friday. The S&P 500 rose 0.2% by midday trading in New York, following a 1% surge last Friday. Both the tech-heavy Nasdaq 100 and blue-chip stocks in the Dow Jones made similar gains. Small caps, as tracked by iShares Russell 2000 ETF (NYSE:IWM), outperformed large-cap stocks, rising as much as 0.9%. Tesla Inc. (NASDAQ:TSLA) g
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister its Securities to terminate and suspend its reporting obligations. Clever Leaves Holdings shares dipped 60% to $1.6498 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares climbed 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash. Collective Audience, Inc. (NASDAQ:CAUD) gained 50.4% to $0.6002 after the company announced a strategic partne
Gainers Deciphera Pharmaceuticals (NASDAQ:DCPH) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Calidi Biotherapeutics (AMEX:CLDI) shares rose 51.46% to $0.24. The market value of their outstanding shares is at $11.9 million. SINTX Techs (NASDAQ:SINT) stock moved upwards by 32.17% to $0.05. The market value of their outstanding shares is at $6.5 million. Koninklijke Philips (NYSE:PHG) stock moved upwards by 28.02% to $26.98. The company's market cap stands at $24.4 billion. As per the news, the Q1 earnings report came out today. Phibro Animal Health (NASDAQ:PAHC) shares rose 26.94% to $16.16. The ma
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. In addition to QINLOCK – Deciphera’s switch-control inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST), which is approved in the U.S. and over 40 other countries, Deciphera also brings a pipeline of cancer drugs such as vimseltinib, DCC-3116 (a ULK inhib